Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach

被引:10
作者
Ascoli, Valeria [1 ]
Minelli, Giada [2 ]
Cozzi, Ilaria [3 ]
Romeo, Elisa [3 ]
Scalzo, Caterina Carnovale [3 ]
Ancona, Laura [3 ]
Forastiere, Francesco [3 ]
机构
[1] Sapienza Univ, Dept Radiol Oncol & Anatomopathol Sci, Viale Regina Elena 324, I-00161 Rome, Italy
[2] Ist Super Sanita, Italys Inst Publ Hlth, Unit Stat, Viale Regina Elena 299, I-00161 Rome, Italy
[3] Lazio Reg Hlth Serv, Dept Epidemiol, Via Cristoforo Colombo 112, I-00147 Rome, Italy
关键词
Malignant pleural mesothelioma; Pathology reporting; Immunohistochemistry; Diagnosis; Cancer registry; EPITHELIOID MESOTHELIOMA; MINIMAL PANEL; IMMUNOHISTOCHEMISTRY; GUIDELINES; CANCER; ANTIBODIES; RECOMMENDATIONS; ADENOCARCINOMA; CONTROVERSIES; EXPRESSION;
D O I
10.1016/j.prp.2016.07.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Accurate pathologic diagnosis and reporting in malignant pleural mesothelioma are essential for clinical care, and cancer registration. Practical guidelines for pathologists are provided in publications and textbooks but it is unclear how these recommendations are applied in routine practice. We investigated the characteristics of pathology reports, and the extent to which they meet guideline standards. We reviewed 819 pathology reports relating to a first diagnosis of malignant pleural mesothelioma. Data sources were a regional section of the Italian network of the Mesothelioma Registry (2001-2014) and a pathology archive (1990-2000). We evaluated tumor characteristics, the diagnosis field including terminology and immunohistochemistry (IHC) workup, and report completeness (the proportion of items recorded). We investigated also two IHC panels identified by the most used markers in current practical guidelines, one best suited for epithelioid mesotheliomas (combinations of at least 2 positive and at least 2 negative mesothelioma markers) and the other best suited for sarcomatoid mesotheliomas (positive mesothelioma markers plus cytokeratins). Reports (753 histology, 66 cytology, IHC-confirmed 86%) were 74% complete and always narrative. Missing data were related to clinical history (76%), tumor laterality (61%), specimen size (38%), and histological subtype (23%). The proportion of cases with IHC was higher for epithelioid (90%) than sarcomatoid mesothelioma (87%). Compliance to IHC recommendations was higher for epithelioid (59%) than sarcomatoid mesothelioma (11%). The mean number of stains was significantly higher for sarcomatoid than epithelioid mesothelioma (p<0.000; Kruskal-Wallis test). Our findings show that although guidelines are designed to improve actual reporting practices, there is ample room for improvement in their application to standardize the diagnosis of mesothelioma. Synoptic pathology reporting needs to be implemented to better utilize pathology information. (C) 2016 Elsevier GmbH. All rights reserved.
引用
收藏
页码:886 / 892
页数:7
相关论文
共 50 条
  • [31] Advances in diagnosis and treatment of malignant pleural mesothelioma
    Scagliotti, Giorgio Vittorio
    Selvaggi, Giovanni
    ONCOLOGY REVIEWS, 2007, 1 (02) : 91 - 102
  • [32] Comparison of Different Clones (WT49 Versus 6F-H2) of WT-1 Antibodies for Immunohistochemical Diagnosis of Malignant Pleural Mesothelioma
    Tsuta, Koji
    Kato, Yasufumi
    Tochigi, Naobumi
    Hoshino, Tatsuhiro
    Takeda, Yuji
    Hosako, Mutsumi
    Maeshima, Akiko Miyagi
    Asamura, Hisao
    Kondo, Tadashi
    Matsuno, Yoshihiro
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2009, 17 (02) : 126 - 130
  • [33] Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
    Kovac, Viljem
    Zwitter, Matjaz
    Zagar, Tina
    RADIOLOGY AND ONCOLOGY, 2012, 46 (02) : 136 - 144
  • [34] Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions
    Canto, A
    Guijarro, R
    Arnau, A
    Galbis, J
    Martorell, M
    Aguado, RG
    THORACIC AND CARDIOVASCULAR SURGEON, 1997, 45 (01) : 16 - 19
  • [35] Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging Consensus of the Austrian Mesothelioma Interest Group (AMIG)
    Geltner, Christian
    Errhalt, Peter
    Baumgartner, Bernhard
    Ambrosch, Gerhard
    Machan, Barbara
    Eckmayr, Josef
    Klikovits, Thomas
    Hoda, Mir Alireza
    Popper, Helmut
    Klepetko, Walter
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (17-18) : 611 - 617
  • [36] Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment
    Ban, Cheng-Jun
    Shi, Huan-Zhong
    Zhang, Yu-Hui
    CHINESE MEDICAL JOURNAL, 2017, 130 (01) : 1 - 3
  • [37] New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
    Rossini, Marika
    Rizzo, Paola
    Bononi, Ilaria
    Clementz, Anthony
    Ferrari, Roberto
    Martini, Fernanda
    Tognon, Mauro G.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [38] Diagnosis, Staging, and Surgical Treatment of Malignant Pleural Mesothelioma
    Michael Kent
    David Rice
    Raja Flores
    Current Treatment Options in Oncology, 2008, 9 : 158 - 170
  • [39] Identification of Novel Markers for the Diagnosis of Malignant Pleural Mesothelioma
    Gueugnon, Fabien
    Leclercq, Sabrina
    Blanquart, Christophe
    Sagan, Christine
    Cellerin, Laurent
    Padieu, Martine
    Perigaud, Christian
    Scherpereel, Arnaud
    Gregoire, Marc
    AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (03) : 1033 - 1042
  • [40] Malignant pleural mesothelioma: an update on diagnosis and treatment options
    Kondola, Sanjana
    Manners, David
    Nowak, Anna K.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) : 275 - 288